NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer | MicrobiomeTrials← Back to trialsNCT04005339
NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2019-07-29Est. Completion: 2025-09-03
Enrollment target: 48 participants Locations- Lombardi Comprehensive Cancer Center, Georgetown University, Washington D.C., District of Columbia, United States
- Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
- Washington University School of Medicine- Siteman Cancer Center, St Louis, Missouri, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
Other microbiome trials you might be interested in
Biliary CancerBile Duct CancerCancer of the Bile Duct
Background:
Biliary tract carcinoma (BTC) is cancer of the slender tubes that carry fluids in the liver. People with ad…
Bethesda, United StatesEst. completion Jun 1, 2040
Advanced Biliary Tract Cancer
The goal of this clinical trial is to learn if the regimen of gemcitabine, toripalimab and dose-modified lenvatinib work…
Multiple LocationsEst. completion Dec 31, 2027